Search
Zai Lab Ltd
ZLABAdd to Watchlist
18.270USD
+0.060+0.33%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.07BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Zai Lab Ltd is 8.33, ranking 41 out of 155 in the Pharmaceuticals industry. The average price target is 48.00, with a high of 67.22 and a low of 23.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
33.876
Target Price
+85.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Zai Lab Ltd
ZLAB
12
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Zai Lab Ltd's expected revenue for the next quarter?
Zai Lab Ltd's expected revenue is 103.81M.
What is Zai Lab Ltd's price target?
Analysts forecast that Zai Lab Ltd's price target is USD 48.00, with the highest forecast at USD 67.22 and the lowest forecast at USD 23.00.
How have Zai Lab LtdZLAB's recent earnings per share performed?
The market expectation was USD -0.46, while Zai Lab LtdZLAB's earnings per share (EPS) for the previous quarter was USD -0.46. EPS for the next quarter is expected at USD -0.60.
What is the analyst rating for Zai Lab Ltd?
Based on the ratings of Zai Lab Ltd's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.